Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Innoviva Inc(INVA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for INVA
11/09/2026: INVA (1-star) is currently NOT-A-BUY. Pass it for now.
Innoviva Inc is a specialized holding company that manages a core portfolio of respiratory pharmaceutical royalties while actively acquiring healthcare and life sciences businesses. Its primary strength lies in the high-margin, predictable cash flow generated by its legacy royalty stream from GSK-partnered drugs. The company is currently executing a strategic shift toward a diversified investment model to mitigate the impact of maturing assets. Key risks include the long-term decline of these legacy royalties and the execution challenges associated with its M&A strategy. The stock may best suit investors comfortable with a transition-phase firm and should be monitored for the success of its recent acquisition integrations.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth is dependent on successful M&A integration rather than traditional organic product pipeline expansion. |
| Momentum investor | Weak fit | Stock performance is often tied to long-term strategic moves rather than short-term price action. |
| Value investor | Mixed fit | Valuation depends heavily on the market's assessment of the current investment portfolio's worth. |
| Dividend investor | Weak fit | The company does not currently offer a consistent or meaningful dividend yield. |
| Low-risk investor | Weak fit | Exposure to pharmaceutical royalty cycles and acquisition integration risk creates significant volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is subject to fluctuations based on royalty performance and M&A news. |
| Valuation risk | Medium | Determining the intrinsic value of diverse investment holdings is inherently complex. |
| Competition risk (Pharmaceutical Royalty) | High | Aggressive competition from other royalty aggregators can inflate acquisition costs. |
| Business quality | Medium | The transition to a holding company structure introduces new operational and management challenges. |
| Dividend income | Low / none | Income investors should not look to this stock for yield. |
| Execution risk | Medium / high | Success relies heavily on identifying and integrating profitable new investments. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 14.95% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.36B USD | Price to earnings Ratio 8.13 | 1Y Target Price 34.8 |
Price to earnings Ratio 8.13 | 1Y Target Price 34.8 | ||
Volume (30-day avg) 823.2K shares | Beta 0.37 | 52 Weeks Range 18.70 - 25.15 | Updated Date 11/08/2026 |
52 Weeks Range 18.70 - 25.15 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.35 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Respiratory Royalties | Royalty income from GSK-partnered drugs (BREO, ANORO). | The company receives a percentage of sales from long-standing respiratory drugs. |
| Investment Holdings | Income from acquired subsidiaries and diversified life science investments. | Innoviva acts like an investment company, aiming to grow capital by acquiring and managing various healthcare businesses. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate 0.49 | Actual 0.5 |
Profitability
Profit Margin 44.13% | Operating Margin (TTM) 39.91% |
Management Effectiveness
Return on Assets (TTM) 7.29% | Return on Equity (TTM) 18.02% |
Valuation
Trailing PE 8.13 | Forward PE 8.56 | Enterprise Value 1.04B | Price to Sales(TTM) 3.1 |
Enterprise Value 1.04B | Price to Sales(TTM) 3.1 | ||
Enterprise Value to Revenue 2.37 | Enterprise Value to EBITDA 3.84 | Shares Outstanding 71.08M | Shares Floating 66.49M |
Shares Outstanding 71.08M | Shares Floating 66.49M | ||
Percent Insiders 1.02 | Percent Institutions 110.93 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.